Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, open-label, two-period, one-sequence, crossover study to evaluate effect of Omeprazole on the pharmacokinetics, safety, and tolerability of Roxadustat in healthy subjects

Trial Profile

A phase 1, open-label, two-period, one-sequence, crossover study to evaluate effect of Omeprazole on the pharmacokinetics, safety, and tolerability of Roxadustat in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2018

At a glance

  • Drugs Roxadustat (Primary) ; Omeprazole
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 18 May 2018 New trial record
    • 11 May 2018 According to results presented at the European Journal of Drug Metabolism and Pharmacokinetics, the study was conducted at the single center (PAREXEL Early Phase Clinical Unit) in Berlin, Germany.
    • 11 May 2018 Results assessing effect of omeprazole on pharmacokinetics, safety and tolerability of Roxadustat were published in the European Journal of Drug Metabolism and Pharmacokinetics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top